Filing Flows › Assembly Biosciences (ASMB) › Q1 2026
Assembly Biosciences (ASMB) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Assembly Biosciences (ASMB) reported revenue of $8.2M for the first quarter 2026 (Q1 2026), -13% from a year earlier and -81% from the quarter before. Operating margin was -138.4%, net loss $9.1M (110.5% of revenue).
Assembly Biosciences, Q1 2026: revenue $8.2M (-13% year over year), operating margin -138.4%, net loss $9.1M, operating cash flow −$22.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.2M | -81% | -13% |
| Operating profit | −$11.4M | — | — |
| Net earnings | −$9.1M | — | — |
| Operating cash flow | −$22.1M | — | — |
What changed
Revenue was $8.2M in Q1 2026, down 13% year over year and down 81% from the previous quarter.
Operating costs exceeded revenue by $11.4M, an operating margin of -138.4%. Total costs grew 1% against a revenue fall of 13%. The quarter ended with a net loss of $9.1M, after a profit of $22.1M the previous quarter. Non-operating items added $2.3M, -25% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$22.1M. Non-cash charges added back $26K of depreciation and amortization and $1.1M of share-based compensation. Working capital and other items used $14.2M. Capital expenditures of $19K exceeded it, leaving free cash flow of −$22.1M.
Questions
What was Assembly Biosciences' revenue in the first quarter 2026?
Assembly Biosciences (ASMB) reported revenue of $8.2M for the first quarter 2026 (Q1 2026), -13% from a year earlier and -81% from the quarter before.
Was Assembly Biosciences profitable in the first quarter 2026?
Operating loss was $11.4M (-138.4% of revenue) and net loss $9.1M.